A TRIAL OF LOBAPLATIN (D-19466) IN PLATINUM-RESISTANT OVARIAN-CANCER

Long-term survival in epithelial ovarian cancer remains problematic de spite multimodality therapy, A fundamental difficulty is the developme nt of tumor resistance to platinum compounds, Analogs have been develo ped that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resist ant cell lines, Lobaplatin was given to 17 assessable patients with pl atinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m(2) but was later reduced to 40 mg/m(2) because of excessive thrombocytopenia, Nine patients required red cell transfusi ons during therapy, Cycles were repeated every 21-35 days (median cycl e length 28 days), No objective responses were observed, Lobaplatin ha s no activity in platinum-resistant epithelial ovarian cancer. (C) 199 5 Academic Press, Inc.